What changed for Rheumatoid Arthritis
A plain English summary of what recently moved in the public data Voxsanity tracks for Rheumatoid Arthritis. Updated from government registries. Not medical advice.
How to read these changes: every figure on this page is the difference between two snapshots of what Voxsanity had tracked on each date. Voxsanity only began taking daily snapshots in July 2026 and is still ingesting the public registries, so a rise here is mostly our own coverage expanding rather than new research appearing. Read it as our tracked coverage growing, not as a claim about real-world research changing this fast: it overstates how much actually changed.
Comparing the two most recent snapshots, 27 July 2026 and 28 July 2026.
- Trials recruiting at Australian sites 14 to 13 (-1)
- Trials recruiting worldwide 186 to 188 (+2)
- Trials on record 2,669 to 2,692 (+23)
Newly subsidised on the PBS
No medicines were newly subsidised on the PBS for Rheumatoid Arthritis in July 2026. Voxsanity tracks 15 PBS-subsidised medicines for this condition; none of them was listed for the first time this month.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.
Past updates
Tracking began in July 2026. Month on month changes will appear here once a second month of data has been recorded. Until then, the comparison above shows the most recent movement.
Recent trend
Weekly, most recent weeks (fills out to a monthly trend as history grows).
Recent trial results
The 30 most recent of 234 trials tracked for Rheumatoid Arthritis that have reported results to a public registry.
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
-
NCT03915964 · results posted 24 June 2026
According to the results reported on ClinicalTrials.gov, this trial (part of a larger program also involving a companion study, NCT04086745) enrolled 886 people in the baricitinib 2 mg group, 886 in the baricitinib 4 mg group, and 887 in the TNF inhibitor (an existing class of arthritis medicine used for comparison) group — roughly 2,659 participants in total at the start. The trial was designed to measure how long it took for participants to experience certain serious medical events — including blood clots in veins (venous thromboembolism), blood clots in arteries, major heart or stroke event...
-
NCT03247023 · results posted 22 June 2026
According to the results reported on ClinicalTrials.gov, this trial enrolled 61 adults who received the Integra® Cadence™ Total Ankle System, an ankle replacement implant. The trial was measuring how long the implant lasted without needing to be removed or replaced, as well as tracking participants' self-reported mobility, ability to carry out daily activities, and ankle pain levels over time. The reported data shows that none of the 61 participants were recorded as having formally "completed" the study under the trial's own milestone definitions, though outcome data was still submitted. The...
-
NCT03905525 · results posted 18 May 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT03905525) enrolled 273 adults with Sjögren's syndrome — a condition that affects moisture-producing glands — across two groups (called cohorts). Cohort 1 included 173 participants and tested three different doses of a medicine called CFZ533 (150 mg, 300 mg, and 600 mg) against a placebo (a dummy treatment with no active ingredient). Cohort 2 included 100 participants and compared CFZ533 600 mg against placebo. The trial ran in two phases of 24 weeks each (48 weeks total). The main things being measured were a doctor-assess...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05576012 · results posted 8 January 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT05576012) enrolled 56 participants in total, split across seven active-treatment groups (called Cohorts 1–7, with 6 participants each) and three placebo groups (10 participants in the placebo group for Cohorts 1–5, and 2 participants each in the placebo groups for Cohorts 6 and 7). Most participants received a single dose of the investigational treatment, while Cohort 6 received multiple doses. The trial was primarily measuring a range of safety-related outcomes, including the number of adverse events (unexpected or unwant...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04539964 · results posted 19 December 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04539964) enrolled 242 people — 122 in the treatment group and 120 in the control group. The trial was looking at outcomes in people with rheumatoid arthritis, a condition that causes joint pain and swelling. The main thing being measured at 12 weeks was whether participants achieved at least a 20% improvement in joint tenderness, joint swelling, and several other measures of how the disease was affecting them (this is called an ACR20 response). A number of secondary measurements were also taken, including other joint-dise...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05516758 · results posted 4 December 2025
According to the results reported on ClinicalTrials.gov, this trial tested a drug called peresolimab in people with rheumatoid arthritis. A total of 491 participants were enrolled across several groups, each receiving different doses of peresolimab (1000 mg, 400 mg, or 100 mg) given by injection under the skin every four weeks, or a placebo (an inactive injection). Some participants later switched doses or frequency during the study. The trial's main goal was to measure how many people in each group showed at least a 20% improvement in a standard set of rheumatoid arthritis signs and symptoms...
-
NCT04488497 · results posted 24 October 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 101 people in total — 49 in a peer coach-guided online learning program and 52 in a self-administered online learning program (the control group). The trial was measuring whether people with a particular health condition would get their blood lipids (fats in the blood, such as cholesterol) checked, and also tracked several questionnaire-based measures including participants' confidence in managing their own health, how actively involved they felt in their own care, their symptom burden, mood, and social support. The...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT06418529 · results posted 31 July 2025
According to the results reported on ClinicalTrials.gov, this study looked at records from 21,340 people in total — 3,681 taking tofacitinib, 11,667 taking a TNF inhibitor (a type of medicine that targets a protein involved in inflammation), 3,528 taking abatacept, and 2,464 taking an IL-6 inhibitor (another type of medicine targeting a different inflammation-related protein). All participants completed the study. The trial was comparing how often people on each of these rheumatoid arthritis medicines reached either "low disease activity" or "remission" — meaning their joint inflammation score...
-
NCT05198310 · results posted 22 July 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT05198310) tested a study drug called KPL-404 in people with rheumatoid arthritis — a condition that causes painful, swollen joints. The trial was divided into four groups (called cohorts) that tested different doses and dosing schedules of KPL-404 compared to a placebo (a dummy treatment with no active ingredient). In total, 145 people started the trial across all groups. The trial measured things like how the drug moved through the body (in the earlier cohorts), changes in joint disease activity over 12 weeks using a scor...
-
NCT04541589 · results posted 29 June 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04541589) was an extension study of an earlier trial looking at a drug called iscalimab. A total of 206 participants took part — 152 people received the higher dose (600 mg) and 54 received the lower dose (300 mg). The trial's primary focus was on recording and counting any unwanted medical events (called adverse events) that occurred during or after treatment. It also measured how much of the drug was present in participants' blood over time, and whether participants' bodies produced antibodies against the drug. The repo...
-
NCT03649061 · results posted 19 June 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT03649061) enrolled 110 people with rheumatoid arthritis — 55 in each group. One group received what the trial called "Standard COBRA-Slim Induction" (a combination of conventional medicines with a short course of steroid), and the other received "COBRA-Slim Bio-induction" (a similar approach but including a biologic medicine). Of the 110 who started, 92 completed the full two-year study (46 in each group). The trial was measuring disease activity over time, as well as a number of other disease-related outcomes at specific...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02699190 · results posted 15 June 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 236 participants in total. Of these, 80 were described as affected patients (people with the condition being investigated), and 156 were their biological parents. All 236 participants completed the study with none dropping out. The trial was looking at whether having a type of detailed genetic test called Whole Genome Sequencing (WGS) — which reads a person's full set of genetic instructions — changed anything for patients in terms of their diagnosis or their ongoing medical care. The reported data shows that for the...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05572567 · results posted 8 June 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT05572567) followed 1,972 people with rheumatoid arthritis in Japan across four treatment groups: 298 taking methotrexate, 663 taking TNF inhibitors (a type of medicine that targets a protein involved in inflammation), 758 taking other non-TNF biologics, and 253 taking tofacitinib. All participants who started the study completed it. The trial was an observational registry — meaning researchers tracked participants in routine care rather than randomly assigning treatments — and it was measuring how often certain health even...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02783274 · results posted 22 May 2025
According to the results reported on ClinicalTrials.gov, this trial looked at the Actis Total Hip System, a type of hip implant. A total of 266 people were enrolled, 255 received the implant, and 191 completed the study. Participants were split into two groups based on the type of procedure they had: 232 people had a total hip replacement (the entire hip joint replaced) and 23 had a partial hip replacement (only part of the joint replaced). The trial used a scoring tool called the Harris Hip Score to measure hip pain, movement, and everyday function at different points in time — at 3 months, 1...
-
NCT01820611 · results posted 20 January 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 74 people who received a hip implant (the Arcos hip stem) coated with a substance called Bonemaster HA, which is designed to help bone attach to the implant. There was only one group in the study — everyone received the same implant. Of the 74 who started, 56 completed the study, and 18 did not complete it. The trial was measuring how many implants remained in place without needing to be replaced after five years, as well as tracking X-ray findings and patients' self-reported quality of life and hip function over time...
-
NCT04947137 · results posted 8 January 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04947137) enrolled 134 people in total: 120 people who were free of inflammatory disease, and 14 people who were either healthy volunteers or had rheumatoid arthritis (RA) and were on stable treatment. All 134 participants who started the trial also completed it. The trial was looking at a substance called tilmanocept, used in a type of body scan, to understand how it shows up in the joints of the hands and wrists — specifically to establish what "normal" levels look like in healthy people and to compare those with reading...
-
NCT04909801 · results posted 15 October 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04909801) enrolled 169 participants in each of two groups — one group received a medicine called abatacept, and the other initially received a different medicine called adalimumab before switching to abatacept in an open-label extension period. The trial was primarily measuring how many participants, specifically those with a particular genetic marker (referred to as "SE+"), showed at least a 50% improvement in rheumatoid arthritis symptoms by week 24, using a standard set of measures known as the ACR50 criteria. Several s...
-
NCT05487703 · results posted 8 October 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 318 participants who were all taking a medicine called tofacitinib. There was only one group in the study — no comparison group. Of the 318 who started, 232 reached the six-month visit point and 209 completed the study, while 109 did not finish. The trial was an observational registry study, meaning it was designed to collect detailed background information about the people taking this medicine rather than to test whether the medicine works. The measurements focused on participants' personal and health characteristics...
-
NCT04888585 · results posted 8 October 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04888585) enrolled 473 adults with rheumatoid arthritis across four treatment groups and a placebo group. In the first 12-week phase, participants received either a placebo (an inactive injection) or one of four different doses of an investigational drug called ABBV-154, given either every two weeks or every four weeks. The trial was primarily measuring how many people achieved at least a 50% reduction in joint tenderness, joint swelling, and several other disease markers — a standard benchmark in rheumatoid arthritis rese...
-
NCT04057118 · results posted 31 July 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04057118) enrolled 163 adults across four groups to test three different daily doses of an investigational medicine called SKI-O-703 (100 mg, 200 mg, and 400 mg) compared with a placebo (an inactive pill) in people with rheumatoid arthritis. The main thing being measured was a standard scoring system called DAS28, which combines information about tender and swollen joints and a blood marker of inflammation to give a picture of how active a person's arthritis is — a higher score means more active disease. Between 36 and 39...
-
NCT02065700 · results posted 4 June 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT02065700) enrolled a total of 739 participants across two groups — 497 in the "Darwin 1" group and 242 in the "Darwin 2" group — all receiving the study drug filgotinib. The trial was a long-term follow-on study measuring undesirable medical events that occurred during treatment, as well as tracking how participants' rheumatoid arthritis symptoms responded over time using standard scoring tools used in arthritis research. The reported data shows that the primary thing being counted was the number of participants who exper...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04605978 · results posted 23 April 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04605978) enrolled 48 people with primary Sjögren's syndrome — a condition that affects the immune system and can cause dryness, fatigue, and joint problems. Thirty-one participants received the active treatment (S95011, given as an infusion into a vein), and 17 received a placebo (an inactive infusion used for comparison). The trial was measuring changes in disease activity and symptoms using several standardised questionnaires and doctor assessments. The primary thing being measured was a doctor-assessed disease activit...
-
NCT04662359 · results posted 16 April 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 18 adults with rheumatoid arthritis (a condition where the immune system attacks the joints, causing inflammation). All 18 participants completed the study — none dropped out. The trial was looking at whether ultrasound scans could be used to measure the level of joint inflammation (called synovitis) in these patients, and whether that ultrasound information had any bearing on the treatment decisions made by their doctors. The reported data shows that the trial used a recognised scoring system where each joint is giv...
-
NCT04333147 · results posted 7 February 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04333147) enrolled 2,915 people in total — 1,456 in the Otilimab 90 mg group and 1,459 in the Otilimab 150 mg group. The trial was measuring the safety profile of two different doses of a medicine called otilimab, tracking things like unwanted medical events (called adverse events), serious adverse events, and certain events flagged as being of special interest. It also measured changes in two blood test results — platelet count (tiny blood cells involved in clotting) and haemoglobin (a protein in red blood cells that carr...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01664598 · results posted 11 December 2023
According to the results reported on ClinicalTrials.gov, this trial enrolled 49 participants, all of whom received the medicine tocilizumab. By the end of the study, 43 participants had completed it, while 6 did not finish. The trial was primarily measuring how often participants experienced unwanted medical events (called adverse events), including serious ones and those of special interest such as serious infections or abnormal liver test results. It also tracked changes in disease activity scores over time using several different measurement tools. The reported data shows that 69.4% of par...
-
NCT04268771 · results posted 18 November 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT04268771) enrolled 140 people in total — 70 in each group. One group received DRL\_RI (a rituximab product being studied as a potential biosimilar, meaning a medicine intended to be very similar to an already-approved one), and the other group received either the US or EU version of the reference rituximab medicine. The trial was primarily measuring whether participants' immune systems produced antibodies against the study medicine — known as "anti-drug antibodies" (ADA) — at several points in time. An anti-drug antibody i...
-
NCT03938636 · results posted 24 August 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT03938636) enrolled 116 people across three groups: 44 people who did not have any inflammatory disease (healthy volunteers), 41 people with rheumatoid arthritis (RA) who were already on a stable treatment, and 31 people with RA who were about to start a new type of medication called an anti-TNFα therapy. The trial was studying a scanning technique that uses a substance called tilmanocept — which is taken up by certain cells in the body — to measure activity in hand and wrist joints. The main goals were to check how consist...
-
NCT02833311 · results posted 12 May 2023
According to the results reported on ClinicalTrials.gov, this trial involved 46 people in total, split across three groups: a Computer Tablet Group (15 people), a Paper and Pencil Group (16 people), and a Standard Treatment Control Group (15 people). The trial was measuring whether different ways of delivering a physical activity program — using a computer tablet, pen and paper, or standard care — were associated with changes in physical activity levels, walking ability, self-reported physical function, confidence in exercising, and body weight. By the end of the study, 43 of the 46 participan...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04163991 · results posted 14 February 2023
According to the results reported on ClinicalTrials.gov, this trial looked at a drug called VIB4920 in people with rheumatoid arthritis (a condition where the immune system attacks the joints). A total of 78 people took part, split across five groups: one group received a placebo (a dummy treatment with no active ingredient), while the other four groups received different doses and dosing schedules of VIB4920. The trial mainly measured changes in joint disease activity using a standard scoring tool called the DAS28-CRP — a scale from 0 to about 10, where higher numbers mean more active disease...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02808871 · results posted 16 August 2022
According to the results reported on ClinicalTrials.gov, this trial (NCT02808871) enrolled 123 participants in total — 63 received pirfenidone (the medicine being studied) and 60 received a placebo (a dummy treatment with no active ingredient). The trial ran for 52 weeks and was measuring things related to lung function, specifically a breathing test called FVC (forced vital capacity, which measures how much air a person can breathe out). The main thing the trial was tracking was how many participants either experienced a significant drop in their lung function (a fall of 10% or more in their...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
See all 234 reported results for Rheumatoid Arthritis
These are the results as reported to the registry, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
What is coming
AI generated pipeline summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to NIH funding data, a substantial amount of public research money is currently directed toward Rheumatoid Arthritis, and that investment has remained broadly steady from year to year. This kind of sustained commitment suggests that researchers and funding bodies continue to see the condition as a meaningful scientific priority. For patients, steady funding at this level generally means...
See the full Rheumatoid Arthritis page
Not medical advice. Voxsanity republishes public government health data in plain English. These figures describe research and registry activity, not the suitability of any treatment for any person. Trial status can change; always verify current status directly with the trial site and confirm Australian availability with your doctor.